BREAST
Scope & Guideline
Shaping the future of oncology with peer-reviewed excellence.
Introduction
Aims and Scopes
- Clinical Research and Trials:
The journal publishes original research articles detailing clinical trials, including phase I, II, and III studies, evaluating the efficacy and safety of new therapies, including chemotherapy, targeted therapy, and immunotherapy for breast cancer. - Diagnostic Techniques and Imaging:
Research focusing on advancements in diagnostic imaging techniques such as mammography, MRI, and PET scans, as well as the development and validation of new diagnostic tools and biomarkers for early detection and monitoring. - Surgical Techniques and Oncoplastic Surgery:
Studies exploring various surgical interventions for breast cancer, including mastectomy, breast-conserving surgery, and oncoplastic techniques, emphasizing outcomes, complications, and innovations in surgical practice. - Patient-Centered Outcomes and Quality of Life:
The journal emphasizes research on quality of life, patient-reported outcomes, and the psychosocial aspects of breast cancer treatment, aiming to improve patient care and support. - Epidemiology and Health Disparities:
Articles addressing the epidemiology of breast cancer, risk factors, and disparities in access to care and treatment outcomes among different populations. - Multidisciplinary Approaches and Care Models:
Research on the integration of multidisciplinary approaches in managing breast cancer, including collaboration between oncologists, surgeons, radiologists, and nurses to enhance patient outcomes. - Innovative Therapies and Molecular Biology:
Focus on the molecular and genetic basis of breast cancer, including studies on targeted therapies, genetic testing, and personalized medicine approaches. - Survivorship and Long-term Outcomes:
Studies evaluating the long-term effects of breast cancer treatment, survivorship issues, and strategies to improve the health and well-being of breast cancer survivors.
Trending and Emerging
- Personalized Medicine and Genomic Testing:
There is a marked increase in research focusing on personalized medicine, including genomic testing and biomarker-driven therapies, which aim to tailor treatment strategies to individual patients. - Immunotherapy and Targeted Therapies:
Emerging studies on immunotherapy and targeted therapies are gaining traction, reflecting a shift towards leveraging the immune system and specific molecular targets in breast cancer treatment. - Telemedicine and Remote Patient Monitoring:
The COVID-19 pandemic has accelerated research into telemedicine and remote monitoring solutions for breast cancer patients, emphasizing the need for accessible care and follow-up. - Long-term Survivorship and Quality of Life:
There is a growing emphasis on the long-term survivorship experience, focusing on quality of life, psychosocial support, and addressing the needs of breast cancer survivors. - Health Disparities and Access to Care:
Research addressing health disparities in breast cancer care, including access to treatment and outcomes among underrepresented populations, is increasingly prominent. - Advanced Imaging Techniques and AI Integration:
Innovations in imaging techniques, including the use of artificial intelligence for better diagnostic accuracy and treatment planning, are emerging as a significant area of interest. - Oncoplasty and Reconstruction Techniques:
Research into oncoplastic surgery and innovative reconstruction techniques is trending, highlighting the importance of aesthetics and function in breast cancer surgery. - Patient-Centric Approaches in Treatment Decisions:
An increasing focus on patient preferences and shared decision-making in treatment planning is emerging, reflecting a shift towards more patient-centered care models.
Declining or Waning
- Traditional Chemotherapy Approaches:
There has been a noticeable decline in studies focusing solely on traditional chemotherapy regimens, as the field shifts towards targeted therapies and personalized medicine approaches. - Standardized Surgical Protocols:
Research on standardized surgical approaches, such as conventional mastectomy without considering personalized techniques, is less prevalent as oncoplastic and individualized surgical methods gain prominence. - Generalized Risk Factors without Stratification:
Studies that broadly address risk factors for breast cancer without stratifying by molecular subtypes or genetic predisposition are becoming less common, reflecting a shift towards more nuanced research. - Basic Epidemiological Studies:
Basic epidemiological studies that do not incorporate advanced methodologies or new insights into breast cancer biology are seeing reduced publication rates, as more complex analyses gain favor. - Non-Molecular Predictive Markers:
Research focusing on non-molecular or traditional predictive markers for treatment response is declining, as the field increasingly emphasizes genomic and molecular profiling.
Similar Journals
Breast Journal
Transforming knowledge into practice for better outcomes.The Breast Journal, published by Wiley-Hindawi, is a distinguished Open Access journal dedicated to the fields of internal medicine, oncology, and surgery with a particular focus on breast health and disease. Since its inception in 1995, the journal has become an essential resource for researchers and clinicians, facilitating the dissemination of high-quality research and innovative clinical practices. With an impact factor reflecting robust scholarly influence and a ranking in the Q3 quartile for both internal medicine and oncology, as well as Q2 in surgery, it showcases significant contributions that advance knowledge and improve patient outcomes. Offering unparalleled access to its articles, The Breast Journal aims to support a global audience in exploring the multifaceted challenges and breakthroughs in breast-related health, making it a vital platform for shared learning and scientific discourse.
ONCOLOGIST
Shaping the future of cancer care through open access.ONCOLOGIST is a premier, open-access journal published by Oxford University Press, advancing the field of cancer research since its inception in 1996. With an impressive H-Index and a prestigious placement within the Q1 category in Cancer Research, Medicine, and Oncology for 2023, ONCOLOGIST stands at the forefront of oncological science, boasting a Scopus rank of #55 out of 404 in Medicine and #47 out of 230 in Cancer Research. This journal not only disseminates cutting-edge research but also aims to foster multidisciplinary approaches that are critical for addressing the complex challenges faced in cancer therapy and survivorship. Be part of a vibrant community as you explore impactful research articles that contribute to the global conversation on cancer. ONCOLOGIST is dedicated to providing an accessible platform for authors and readers alike, ensuring that high-quality research is available to all stakeholders in the fight against cancer.
Gland Surgery
Innovating the future of gland surgery through research.Gland Surgery, an esteemed journal published by AME PUBLISHING COMPANY, is at the forefront of surgical research, particularly focusing on advancements in gland-related surgeries and their clinical implications. With an ISSN of 2227-684X and an E-ISSN of 2227-8575, this open-access journal provides a platform for disseminating high-quality research and insights into the intricate aspects of surgical practices, ranking in the Q2 category in Surgery as of 2023. As evidenced by its Scopus ranking at #153 out of 551 in the Medicine_Surgery field, Gland Surgery delivers valuable contributions to the global medical community, promoting the exchange of knowledge and innovative techniques. Operating from Hong Kong, China, and converging its excellence from 2016 to 2024, the journal is a critical resource for researchers, clinicians, and students keen on exploring the latest developments in the field. By fostering an open dialogue among professionals, Gland Surgery is accessible to a diverse audience seeking to enhance their understanding and practice in gland surgery.
PROSTATE
Pioneering insights for better male health outcomes.PROSTATE is a premier, peer-reviewed journal published by Wiley, focusing on the critical fields of urology and oncology. With an established history since 1980 and a projected convergence through 2024, this influential journal serves as a vital resource for researchers, clinicians, and students alike. It holds a prestigious position in the academic landscape, classified in the Q1 category for Urology and Q2 in Oncology as of 2023, demonstrating its significant contribution to these disciplines. With a Scopus rank of #23 in Urology and #169 in Oncology, PROSTATE is pivotal for advancing knowledge and fostering innovation in prostate research, treatment, and overall male health. The journal aims to publish high-quality original articles, reviews, and clinical studies that address the complexities of prostate-related conditions, ultimately seeking to improve patient outcomes and propagate best practices in the medical community.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Championing Excellence in Cancer Research and Clinical Practice.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.
BRITISH JOURNAL OF CANCER
Advancing Cancer Knowledge Through Rigorous Research.The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.
Breast Cancer Management
Elevating Standards in Breast Cancer Management.Breast Cancer Management is a pivotal journal in the field of oncology and radiology, published by FUTURE MEDICINE LTD. Since its transition to Open Access in 2018, the journal has aimed to democratize access to cutting-edge research focused on innovative treatments and management strategies for breast cancer. With an ISSN of 1758-1923 and an E-ISSN of 1758-1931, it provides a platform for researchers and clinicians to share findings that enhance patient care and outcomes. The journal has garnered significant attention, placing in the Q3 quartile in Oncology and Q2 in Radiology, Nuclear Medicine, and Imaging as of 2023. Positioned in the United Kingdom, its editorial focus and rigorous peer-review process ensure that it remains at the forefront of breast cancer research. As breast cancer continues to be a major health concern globally, Breast Cancer Management serves as an essential resource for advancing knowledge and fostering collaboration among professionals in this vital area of medicine.
Cancer Medicine
Advancing cancer care through innovative research.Cancer Medicine is a leading open access journal published by WILEY, focusing on innovative research and advancements in the fields of Cancer Research, Oncology, and Radiology, with an impressive impact evidenced by its 2023 Q2 ranking in Cancer Research and Q1 rankings in both Oncology and Radiology, Nuclear Medicine and Imaging. With an ISSN of 2045-7634, this journal has been committed to disseminating pivotal findings since its inception in 2012, serving as a vital platform for researchers, practitioners, and students alike. The journal proudly embodies the spirit of open access, ensuring that groundbreaking cancer research is accessible to a global audience. Located in the United Kingdom, it spans a wide array of topics, promising comprehensive insights into cancer therapies, molecular mechanisms, and imaging techniques, thereby significantly contributing to the enhancement of cancer care and treatment outcomes. Researchers interested in exploring the latest advancements in cancer medicine will find this journal an indispensable resource.
BREAST CANCER RESEARCH AND TREATMENT
Empowering Researchers, Enhancing LivesBreast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.
JNCI-Journal of the National Cancer Institute
Driving excellence in cancer research since 1940.JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.